Cepheid, Others Look Beyond Respiratory Infections in the Molecular POC Diagnostics Market

Companies looking beyond the clinical lab in the molecular diagnostics market predominately target rapid test demand in primary care and critical care, chiefly respiratory infections. All CLIA waivers to date for molecular tests have been for respiratory infections (influenza, strep A, RSV), though equally ample and more promising markets for molecular point-of-care (POC) diagnostics market will be found in other areas - including women’s health/sexual health and high-burden diseases in the deve...


Top Infectious Diseases in the IVD Market - HIV

The following analysis is derived from Kalorama Information’s recently released global market research report: The Worldwide Market for Infectious Disease Diagnostic Tests.

This is the second in a series of five posts outlining the leading infectious diseases or disease groups in terms of IVD market sales.

At over $2 billion in IVD market revenue, diagnostic tests for human immunodeficiency virus (HIV) infections are found across segments, including immunoassays, molecular assays, and blood ...

  • by bcarlson@marketresearch.com
  • November 5 2013
  • HIV


Spread of Infectious Disease Drives New Diagnostic Markets

Spread of Infectious Disease Drives New Diagnostic Markets

Increasing incidence of infectious disease is expected to make the market for infectious disease among the most dynamic in the in vitro diagnostics industry, according to Kalorama Information. The world market for infectious disease tests is estimated at $14.5 billion in 2012 and should grow at a slightly higher rate than the rest of the diagnostics market. The finding was made in our new report, The World Market for Infectious Disease Diagnostic Tests.

“Unfortunately for world populations, th...